Intracellular Therapeutics Pipeline
Diverse and Expanding Pipeline of Programs Spanning Discovery and Clinical Development
At Entrada Therapeutics, we are driven to transform the lives of patients by establishing a new class of intracellular therapeutics. We are already developing potential treatments across multiple devastating diseases with a simple and scalable EEV platform designed to translate from preclinical to clinical development.
Learn more about our proprietary EEV™ Platform.
Information is current as of November 6, 2025, updates are made on a quarterly basis.
Duchenne Muscular Dystrophy (DMD)
To learn more about Duchenne muscular dystrophy, visit our DMD Page.
ENTR-601-44 (Exon 44 Skipping Oligonucleotide)
Discovery
100%
complete
Lead Optimization
100%
complete
IND Enabling
100%
complete
Clinical
22%
complete
ENTR-601-45 (Exon 45 Skipping Oligonucleotide)
Discovery
100%
complete
Lead Optimization
100%
complete
IND Enabling
100%
complete
Clinical
13%
complete
ENTR-601-50 (Exon 50 Skipping Oligonucleotide)
Discovery
100%
complete
Lead Optimization
100%
complete
IND Enabling
100%
complete
Clinical
0%
complete
ENTR-601-51 (Exon 51 Skipping Oligonucleotide)
Discovery
100%
complete
Lead Optimization
100%
complete
IND Enabling
75%
complete
Clinical
0%
complete
Myotonic Dystrophy Type 1 (DM1)
To learn more about Myotonic dystrophy type 1, visit our DM1 Page.
VX-670 (Oligonucleotide) 1
Discovery
100%
complete
Lead Optimization
100%
complete
IND Enabling
100%
complete
Clinical
40%
complete
Pipeline Expansion
Undisclosed Ocular
Discovery
100%
complete
Lead Optimization
90%
complete
IND Enabling
0%
complete
Clinical
0%
complete
Undisclosed Programs
Discovery
100%
complete
Lead Optimization
55%
complete
IND Enabling
0%
complete
Clinical
0%
complete
Platform Expansion
Discovery
100%
complete
Lead Optimization
0%
complete
IND Enabling
0%
complete
Clinical
0%
complete
References
-
1.
In collaboration with
